Objective To investigate whether in utero opioid exposure, which has been linked to adverse neurodevelopmental and social outcomes, is associated with altered DNA methylation of opioid-related genes at birth.
M
ethadone maintenance is the international standard of care for pregnant opioid dependent women. 1 Despite the advantages of methadone in stabilizing maternal lifestyle, there are problems associated with its use. Infants of methadone-maintained opioid-dependent (MMOD) mothers have shorter gestation periods, lower birth weights, smaller head circumferences, and are at risk of developing neonatal abstinence syndrome (NAS). 2, 3 Visuocortical function is impaired at birth, 4 and the adverse effects of in utero opioid exposure continue into early childhood, adversely impacting upon visual development as well as cognitive, psychomotor, and behavioral performance. [5] [6] [7] It is not clear to what extent factors such as poverty and coexistent illicit drug and alcohol misuse contribute to adverse outcomes for infants of opioiddependent mothers. Social and psychological problems may persist to adulthood, and there is some evidence of intergenerational substance misuse, particularly between substance misusing mothers and their daughters, although the mechanisms of this are poorly understood. 8, 9 Mechanisms by which opioids may influence fetal development include inhibition of neuronal proliferation and differentiation with increased cell death, alterations in endocrine function, and modifications to myelin sheath formations, 5, 10 and it is feasible that fetal and later childhood outcomes of opioid-exposed pregnancies are influenced by in utero changes to DNA methylation. 11 Increased DNA methylation on the µ-opioid receptor gene (OPRM1) in sperm and white blood cells in adult subjects has been attributed to opioid misuse, [12] [13] [14] and has also been described in relation to the development of NAS in methadoneexposed newborns. 15 To date no studies have reported DNA methylation of opioid-related genes in infants of MMOD mothers compared with opioid-naïve infants.
The aims of this study were to compare differences in DNA methylation on selected opioid-related genes (ABCB1, CYP2D6, and OPRM1) between MMOD mothers and their newborn infants and opioid-naive mothers and their newborn infants, and to examine whether DNA methylation in the newborn is associated with in utero growth, development of NAS, or length of hospital stay. We also sought 
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to investigate whether maternal cigarette smoking or postcode of resident (as a proxy for socioeconomic deprivation) influence DNA methylation in the newborn.
Methods
All MMOD mothers delivering after 36 completed weeks of gestation at Princess Royal Maternity in Glasgow were eligible to participate in the study. Potential subjects were identified in the postnatal wards soon after delivery. These mothers had been managed within an established multidisciplinary service for women with social problems including substance misuse; antenatal care included ongoing methadone maintenance provided in collaboration with social work and addiction services and tailored to symptoms. Sufficient methadone was prescribed to eliminate physical withdrawals, with the aim of reducing toward the lowest acceptable dose of methadone in the weeks before delivery. Exclusion criteria included unwell babies and those born before 36 completed weeks of gestation. Within 24-72 hours of delivery and following informed parental consent, a buccal swab (Catch-All; Cambio Ltd, Cambridge, United Kingdom) was obtained from the baby and a venous blood sample obtained from the mother for estimation of trough plasma methadone concentration. The latter was drawn shortly before administration of the once daily prescribed dose of methadone. Demographic data including maternal age, prescribed methadone dose at delivery, smoking status, and postcode of residence were extracted from case records. Deprivation score (DEPCAT) was calculated from postcode using Carstairs index. 16 Use of other drugs (illicit or prescribed) was determined from case records and from individual discussion with mothers as well as from urine samples immediately postnatally, when available. Routine antenatal urine toxicology was not hospital policy and, thus, was not included in this study.
Infant gestation, birth weight, and length of hospital stay were also recorded from case records. All babies were nursed in the postnatal ward with their mothers and NAS was managed according to protocol; scoring used a local version of the Lipsitz scale. 17 Infants scoring 5 or more on 2 consecutive occasions and/or with poor feeding or ongoing weight loss after 5 days were commenced on oral morphine at a dose of 60 µg/kg 6 times daily. Treatment was escalated to 80 µg/kg/dose if the baby remained symptomatic otherwise morphine was weaned daily by 10 µg/kg/dose. If NAS symptoms were not controlled by oral morphine, phenobarbital was given in addition. Regardless of treatment, all infants remained with their mother in hospital for a minimum of 5 days. Length of stay for treated babies was determined by success of weaning of morphine; for treatment periods greater than 10-12 days, the mother was discharged from hospital and the baby admitted to the neonatal unit. Following weaning of oral morphine, phenobarbital treatment could be continued as an outpatient. Breast feeding was encouraged for all babies. The research team was not involved in any decision to treat an infant.
To control for the effects of cigarette smoking and poverty on DNA methylation, 2 groups of nonopioid-dependent mother-infant dyads were recruited from the postnatal wards of the same maternity hospital, based on maternal smoking (yes or no) and postcode of residence. Cigarette smoking mothers from DEPCAT scores 4-7 comprised a "deprived" group and nonsmoking mother-infant dyads from more affluent areas of Glasgow (DEPCAT 1-3) an "affluent" group. Oral swabs were obtained from opioid-naïve mothers and infants within 24-48 hours of delivery and maternal age, infant birth weight, and gestation recorded. Infant buccal swabs were collected before commencement of treatment for NAS. All mothers and babies were of Caucasian origin.
Limited funding allowed for investigation of 50 motherinfant dyads in this pilot study; we aimed, therefore, to recruit 20 MMOD and 15 each deprived and affluent nonopioidexposed dyads. The study was approved by West of Scotland Research Ethics Committee 5, and all mothers gave informed, written consent.
DNA extracted from buccal swabs underwent bisulfite conversion using the EZ DNA Methylation-Gold kit protocol (Zymo Research, Frieburg, Germany) and was amplified by a Veriti Thermal Cycler (Life Technologies, Carlsbad, California). Percentage methylation was quantified using the Q24 Pyrosequencer (Qiagen, Hilden, Germany). Details of the primers used are listed in Table I (available Methadone was isolated from 1 mL of plasma at the Toxicology Unit, Imperial College, London by liquid-liquid extraction, using clomipramine-D3 as the internal standard. Quantification was undertaken using a Hewlett Packard 6890 gas chromatograph linked to a 5973 mass spectrometer (Hewlett Packard, Avondale, Pennsylvania).
Statistical Analyses
Statistical analyses were conducted using SPSS v 23 (SPSS Inc, Chicago, Illinois). Maternal age, gestation, birth weight, and gene methylation differences between the opioid-exposed and naïve mother, and infant populations were determined using 1-way ANOVA, as were the differences between gene methylation and requirement for NAS treatment. The data were interrogated for outliers by visually inspecting box plots, and normality was assessed using the Shapiro-Wilk test. If either of these tests were violated, the data were transformed. If transformation of the data did not produce normal distribution, Welch and Games-Howell post-hoc tests were undertaken. For normally distributed data with no outliers, Tukey post-hoc tests were carried out.
Results
Twenty-one of 22 consecutively delivered MMOD mothers approached agreed to participate in the study, and samples were Volume 190 • November 2017 obtained from all 21 mother-infant dyads. In addition, 17 deprived and 15 affluent (opioid-naïve) mother-infant dyads were recruited. Affluent and MMOD mothers were of similar age (median 32 years); deprived mothers were younger (28 years, P = .02) ( Table II) . Gestation ranged from 36 +1 to 42 +0 (mean 38 +6 ) weeks and did not differ between opioid-exposed and opioid-naïve infants born in either affluent or deprived postcodes. Birth weight did not differ between affluent and deprived controls but was lower in the MMOD group than combined controls (2815 ± 352.5 g vs 3386 ± 533.7 g, P < .0005). Median hospital stay for infants of MMOD mothers was 11 days (range 5-42 days); opioid-naïve infants were discharged home with their mothers within 24-72 hours after birth, depending on mode of delivery.
MMOD mothers had been prescribed a mean daily methadone dose of 59 ± 27.6 mg at delivery. Plasma samples were obtained from 18 of 21 MMOD mothers; median methadone plasma concentration was 245 (range 60-720 µg/L). In addition to prescribed maintenance methadone, all MMOD mothers had smoked cigarettes, and a majority admitted to consumption of other drugs, including heroin (smoked or injected), prescription and/or illicit benzodiazepines, and cannabis. Eleven of 21 infants born to MMOD mothers required treatment for NAS; 2 of these treated babies additionally required phenobarbital.
There was little variation in methylation between CpG sites for each of the genes studies, and so averaged results were used.
ABCB1 methylation was assessed for 20 opioid-naïve infants, 9 opioid-naïve mothers, 19 opioid-exposed infants, and 18 MMOD mothers. ABCB1 methylation was the same in opioidnaïve mothers and infants, and in opioid-exposed mothers and their infants, but was significantly higher in the opioidexposed mother-infant dyads, compared with opioid-naïve subjects (3 ± 0.5% in opioid naïve newborns; 3 ± 0.4% in opioid naïve mothers; 18 ± 4.8% in opioid exposed newborns; 16 ± 8.3% in MMOD mothers (Welch F [3, 28. 174] = 56.031, P < .0005) (Figure) .
CYP2D6 methylation was assessed for 32 opioid-naïve infants and their mothers and for 18 MMOD mothers and their infants. There were no differences between opioid-naïve or opioidexposed infants and their mothers (Figure) . CYP2D6 methylation was marginally but significantly higher in MMOD mothers (92 ± 1.7%) and their infants (92 ± 1.2%) compared with opioid-naïve mothers (89 ± 4.2%) and their infants (89 ± 2.4%) (Welch F [3, 48 .083] = 14.755, P < .0005).
OPRM1 methylation was assessed for 30 opioid-naïve infants, 29 opioid-naïve mothers, 20 opioid-exposed infants, and 19 MMOD mothers. OPRM1 methylation was significantly lower in opioid-naïve infants (3 ± 1.6%) compared with opioidnaïve mothers (8 ± 2.0%), opioid-exposed infants (8 ± 0.3%), and in MMOD mothers (9 ± 0.1%). Games-Howell post hoc analysis; −4.61 (95% CI −5.90 to −3.33; P < .0005), 4.99 (95% CI −5.81 to −4.17; P < .0005), and −5.20 (95% CI −6.03 to −4.36; P < .0005), respectively (Figure) .
There was no relationship between infant DNA methylation of any of the genes studied and either birth weight, length of hospital stay, maternal dose, or plasma concentration of methadone. DNA methylation was not different between opioid-exposed newborns who did or did not require treatment for NAS (Table III) . Figure. ABCB1, CYP2D6, and OPRM1 gene DNA methylation in MMOD mothers and their newborns compared with opioid-naïve mothers and newborns. Opioid-exposed newborns had higher % methylation than opioid naive newborns on all genes investigated. Similar methylation was observed on the OPRM1 gene between MMOD and opioid naïve mothers, however, methylation was higher on ABCB1 and CYP2D6 in MMOD mothers. White filled column = opioid-naïve newborns; solid grey column = opioid-exposed newborns; checkered white filled column = opioid-naive mothers; checkered gray filled column = MMOD mothers.
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Discussion
We explored DNA methylation on ABCB1 and CYP2D6 genes in methadone exposed newborns, and also compared DNA methylation between opioid-exposed and opioid-naïve newborns. We found DNA methylation of all 3 opioid-related genes in newborn infants of MMOD mothers to be similar to that of their mothers, and higher than that of opioid-naïve newborns. Increased methylation on OPRM1 is consistent with the study of Wachman et al 15 who analyzed a larger population (n = 86) of infants exposed to maternal opioids, 65% of whom required pharmacologic treatment for NAS. Our failure to confirm an association between increased methylation of the OPRM1 promoter and severity of NAS may well be a type II error, reflective of our smaller study numbers.
Opioid misuse is associated with numerous lifestyle factors deleterious to health. We did not have accurate toxicology data to confirm additional substance use, but from previous studies in a very similar population, we assume that this was common and most likely to be illicit opioids and benzodiazepines.
2 Prenatal exposures to antidepressants, antiepileptic drugs, alcohol, antibiotics, and tobacco have all been associated with altered neonatal DNA methylation. [18] [19] [20] [21] [22] [23] We did not see an effect of cigarette smoking upon DNA methylation in opioid-naïve newborns, but study numbers were small. Socioeconomic deprivation may also have contributed to increased DNA methylation in opioid-exposed mother-infant dyads. 24 We did not find any differences between opioid-naïve "deprived" and "affluent" dyads, but we acknowledge that numbers were small, and that postcode of residence is a poor proxy for social deprivation. Besides small patient numbers, a limitation of the present study is that the nutritional intake of mothers was not obtained. It is, therefore, not possible to conclude if the increased DNA methylation of ABCB1, CYP2D6, and OPRM1 genes observed in opioid-exposed newborns was due to maternal prescribed substitute methadone, ongoing illicit drug use, or other lifestyle factors associated with drug misuse.
Disparity in gene methylation between opioid-exposed and opioid-naïve infants could have originated during any stage of fetal development. Fertilization and early embryogenesis is a particularly sensitive period of epigenetic reprograming when paternal and maternal genomes are actively and passively demethylated to facilitate the conversion from somatic to germline epigenotype that enables cell differentiation. 25 A plausible mechanism by which methadone could increase DNA methylation is through G-protein-coupled receptor-mediated increase of DNA methyltransferase activity, 14 mediated by activation of mitogen-activated protein kinase-dependent pathways. 26, 27 Higher maternal DNA methylation on ABCB1 and OPRM1 observed in opioid-naïve dyads would be predicted as a result of age associated epigenetic alterations of CpG rich regions 28 whereas the lack of difference between opioid-naïve mother and infant CYP2D6 gene methylation could be a tissue specific phenomenon. CYP2D6 gene expression is not necessary in buccal DNA and may not reflect methylation of brain DNA.
The association of hypermethylation with methadone treatment suggests interaction between opioids and mechanisms of classical epigenetics. 29 Global DNA methylation analysis 18 would have addressed whether our observations reflect a global increase in DNA methylation rather than a specific effect upon a few genes but was beyond the scope and purpose of this particular study. DNA methylation of ABCB1, CYP2D6, and OPRM1 opioidrelated genes is increased in newborn infants of MMOD mothers, but the mechanisms of this are not clear. The effect of this phenomenon should be explored in relation to the infant's behavior and susceptibility to disease and drug use later in life. ■ 
